Opendata, web and dolomites

ClearRing SIGNED

An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ClearRing project word cloud

Explore the words cloud of the ClearRing project. It provides you a very rough idea of what is the project "ClearRing" about.

urinary    rapid    urological    worldwide    resume    preservers    patients    clinical    severity    health    hyperplasia    million    validate    alternative    efficacy    normal    twice    tolerable    medical    company    centres    chance    implant    presses    migration    blocks    watchful    comparatively    age    unmet    significantly    introduce    carry    ce    solution    patient    proarc    undesirable    worsening       obtain    shaped    drugs    position    costly    benign    gradually    surgery    symptoms    procedure    complications    seek    prostate    reduces    fast    operation    invasive    waiting    men    revolutionary    standard    validation    minimally    whereas    lifestyles    affordable    first    treatment    enlargement    potentially    implantable    hospitals    life    causing    clearring    safe    puts    urethra    reimbursement    diseases    90    risk    quality    bothersome    70    mark    trial    200    enlarges    therapy    encrustation    instead    efficient    function    prostatic    inside    60s    authorisation    bph    randomized    safety    sexual   

Project "ClearRing" data sheet

The following table provides information about the project.

Coordinator
PROARC MEDICAL LTD 

Organization address
address: KIDMA 23
city: PARDES HANA
postcode: 3707923
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 2˙776˙750 €
 EC max contribution 1˙943˙725 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROARC MEDICAL LTD IL (PARDES HANA) coordinator 1˙943˙725.00

Map

 Project objective

Benign Prostatic Hyperplasia (BPH), or prostate enlargement, is one of the most common urological diseases among men. As the prostate enlarges with the age, it presses on and blocks the urethra, causing bothersome urinary symptoms. Over 70% of men in their 60s have symptoms of BPH 1, and 80-90% of men over 80 year old. BPH affects around 200 million men worldwide. The current methods present a significant unmet need for minimally invasive or less invasive BPH therapy as a less costly, more tolerable, and comparatively safe alternative to drugs and invasive surgery, which carry greater risk of undesirable side effects and complications. ClearRing is a revolutionary treatment of BPH symptoms, based on a pre-shaped implant and a dedicated delivery system. The ClearRing solution is the only minimally invasive system for BPH which is implantable inside the prostate with 0% chance of migration or encrustation. It puts ProArc in a unique position as a first company providing significantly improved health conditions and quality of life. Its rapid procedure enables hospitals to get patients in and out more quickly, creating a better patient experience as well as a more efficient management of medical resources. The minimally invasive procedure reduces the range and severity of side effects allowing patients to resume their normal lifestyles potentially twice as fast as the current standard operation procedure. Furthermore, it preservers sexual function. Overall objective of ProArc is to introduce a BPH treatment which is effective, affordable and with no side-effects, therefore men seek for the treatment instead of watchful waiting for the worsening. Whereas, the key objective of the project is to validate the ClearRing safety and efficacy for BPH treatment through a randomized clinical trial at 3 medical centres. This large scale clinical validation will enable ProArc to obtain the CE mark, and gradually apply for the reimbursement authorisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CLEARRING" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CLEARRING" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More